Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Non-cash Items (2021 - 2025)

Rani Therapeutics Holdings has reported Non-cash Items over the past 5 years, most recently at $7.2 million for Q4 2025.

  • Quarterly results put Non-cash Items at $7.2 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $7.2 million (changed N/A YoY), and the annual figure for FY2025 was $7.2 million, changed.
  • Non-cash Items for Q4 2025 was $7.2 million at Rani Therapeutics Holdings, up from $6.5 million in the prior quarter.
  • Over the last five years, Non-cash Items for RANI hit a ceiling of $27.8 million in Q1 2022 and a floor of $57806.0 in Q3 2021.
  • Median Non-cash Items over the past 5 years was $6.8 million (2025), compared with a mean of $8.7 million.
  • Peak annual rise in Non-cash Items hit 16680.27% in 2022, while the deepest fall reached 16680.27% in 2022.
  • Rani Therapeutics Holdings' Non-cash Items stood at $976000.0 in 2021, then soared by 893.85% to $9.7 million in 2022, then skyrocketed by 37.91% to $13.4 million in 2023, then plummeted by 64.76% to $4.7 million in 2024, then skyrocketed by 52.27% to $7.2 million in 2025.
  • The last three reported values for Non-cash Items were $7.2 million (Q4 2025), $6.5 million (Q2 2025), and $16.4 million (Q1 2025) per Business Quant data.